Mediar Therapeutics
Boston, US · Founded 2018 · Delaware corporation · 58 employees on LinkedIn · 9 known investors
Find your way into Mediar Therapeutics
586 people in our graph share verified history with the Mediar Therapeutics team — schools, employers, funds. One of them is your warm intro.
Anthony Philippakisunlockedknows Rahul Ballal · together at Broad Institute (overlapped)
×2knows the team · via Agios Pharmaceuticals
×6knows the team · via Broad Institute
×2knows the team · via MIT Sloan School of Management
knows the team · via The Johns Hopkins University
Mediartx develops novel therapies for patients with fibrotic diseases.
Founders & leadership
RB
Rahul Ballal, PhDCEO
PY
RB
Rahul BallalinCEORahul Ballal is a biotech executive with over 15 years of experience in building companies and financing. He previously served as president and CEO of Imara, guiding the company from Series A through its IPO and merger with Enliven Therapeutics, and held prior roles including chief business officer at Northern Biologics, vice president of business development at Flexion Therapeutics, and entrepreneur-in-residence at Versant Ventures. He holds a Ph.D. in biochemistry from Georgetown University, an M.S. in bioinformatics from Johns Hopkins University, and a B.S. in biology from Brown University.
BH
Brian HubbardNamed on SEC filing
SB
Stacey BrennerNamed on SEC filing
DD
David de GraafNamed on SEC filing
Board
MB
Michael BaranBoard director
MF
Meredith FisherinCo-founding CEO and Director2019–2023General Partner at Mass General Brigham Ventures
AJ
AK
CB
MB
Investors · 9
Agent CapitalWaltham
Longwood FundBoston
Mission BiocapitalSan Francisco · $500K
Novartis Venture FundBasel · $5M – $25Mvia Anja Koenig · board
Ono Venture Investment, Inc.South San Francisco
Pfizer Venture Investments$5M – $20M
ShangBay Capital LLCPalo Alto
Sofinnova PartnersParis · $540K – $27Mvia Maina Bhaman · board
Pfizer Venturesreported
Reported raises · per SEC filings
Form D private placements$127.9M disclosed across 3 rounds · 2019–2025
▶$37.8MraisedDec 2025 · 18 investors · BiotechnologyRule 506(b)
▶$37.8MraisedDec 2025 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andreas JurgeitDirector
- Bharat SrinivasaDirector
- Allan MarchingtonDirector
- Rahul BallalExecutive Officer, Director
- Cassidy BlundellDirector
- Maina BhamanDirector
- Adam CottonDirector
- Simon SturgeDirector
- Marie-Claire PeakmanDirector
- Offering amount
- $75.7M
- Amount sold
- $37.8M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$85MraisedOct 2024 · 17 investors · BiotechnologyRule 506(b)
▶$85MraisedOct 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Simon SturgeDirector
- Michael BaranDirector
- Meredith FisherDirector
- Andreas JurgeitDirector
- Anja KonigDirector
- Rahul BallalExecutive Officer, Director
- Cassidy BlundellDirector
- Maina BhamanDirector
- Offering amount
- $85M
- Amount sold
- $85M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedFeb 2019 · 7 investors · OtherRule 506(b)
▶$5MraisedFeb 2019 · 7 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Brian HubbardDirector
- Stacey BrennerExecutive Officer
- Peter ParkerDirector
- David de GraafDirector
- Meredith FisherDirector
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Mediar Therapeutics went on to found or lead other companies.
Competitors · 2
by search overlapBioworld14 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Mozart Therapeutics9 shared keywordsMozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments. The company is founded on research from Stanford University scientists and is led by experienced biopharmaceutical industry executives.
Companies competing with Mediar Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Mediar Therapeutics do?
- Mediartx develops novel therapies for patients with fibrotic diseases.
- Who are Mediar Therapeutics's investors?
- Mediar Therapeutics's investors include Agent Capital, Longwood Fund, Mission Biocapital, Novartis Venture Fund, Ono Venture Investment, Inc., Pfizer Venture Investments, ShangBay Capital LLC, Sofinnova Partners and 1 more.
- How much funding has Mediar Therapeutics raised?
- Mediar Therapeutics has disclosed $127.9M raised across 3 rounds.
- Where is Mediar Therapeutics headquartered?
- Mediar Therapeutics is headquartered in Boston, US.